Sarepta gains after appointing former AbbVie executive Severino as CEO
27/07/2026 14:04
BUZZ-Sarepta gains after appointing former AbbVie executive Severino as CEO ** Shares of gene therapy co Sarepta Therapeutics SRPT.O rise 7.1% to $16.8 premarket
** Co appoints Michael Severino as CEO, effective from July 28
** Severino succeeds Doug Ingram, who is retiring and will hold an advisory post till the end of the year for a smooth transition
** Before joining co, Severino served as the CEO of Tessera Therapeutics and previously held the positions of Vice Chairman and President in AbbVie ABBV.O
** As of last close, stock has fallen 27.1% YTD
(Reporting by Anand Gopal in Bengaluru)
Recent news on Sarepta Therapeutics
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure